{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:56:37Z","timestamp":1787964997784,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-71446-8","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T15:03:20Z","timestamp":1725375800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy"],"prefix":"10.1038","volume":"14","author":[{"given":"Takuya","family":"Iino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nishimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amane","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"71446_CR1","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1136\/jnnp-2021-327909","volume":"93","author":"A Carroll","year":"2022","unstructured":"Carroll, A. et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J. Neurol. Neurosurg. Psychiatry 93, 668\u2013678. https:\/\/doi.org\/10.1136\/jnnp-2021-327909 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"71446_CR2","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.7754382","volume":"268","author":"HL Monaco","year":"1995","unstructured":"Monaco, H. L., Rizzi, M. & Coda, A. Structure of a complex of two plasma proteins: Transthyretin and retinol-binding protein. Science 268, 1039\u20131041. https:\/\/doi.org\/10.1126\/science.7754382 (1995).","journal-title":"Science"},{"key":"71446_CR3","doi-asserted-by":"publisher","first-page":"8654","DOI":"10.1021\/bi00151a036","volume":"31","author":"W Colon","year":"1992","unstructured":"Colon, W. & Kelly, J. W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31, 8654\u20138660. https:\/\/doi.org\/10.1021\/bi00151a036 (1992).","journal-title":"Biochemistry"},{"key":"71446_CR4","doi-asserted-by":"publisher","first-page":"E6201","DOI":"10.1073\/pnas.1807024115","volume":"115","author":"X Sun","year":"2018","unstructured":"Sun, X., Dyson, H. J. & Wright, P. E. Kinetic analysis of the multistep aggregation pathway of human transthyretin. Proc. Natl. Acad. Sci. USA 115, E6201\u2013E6208. https:\/\/doi.org\/10.1073\/pnas.1807024115 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71446_CR5","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg, F. L., Grogan, M., Hanna, M., Kelly, J. W. & Maurer, M. S. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J. Am. Coll. Cardiol. 73, 2872\u20132891. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"71446_CR6","doi-asserted-by":"publisher","first-page":"11442","DOI":"10.1021\/bi011194d","volume":"40","author":"X Jiang","year":"2001","unstructured":"Jiang, X. et al. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 40, 11442\u201311452. https:\/\/doi.org\/10.1021\/bi011194d (2001).","journal-title":"Biochemistry"},{"issue":"Suppl 4","key":"71446_CR7","doi-asserted-by":"publisher","first-page":"16427","DOI":"10.1073\/pnas.202495199","volume":"99","author":"P Hammarstrom","year":"2002","unstructured":"Hammarstrom, P., Jiang, X., Hurshman, A. R., Powers, E. T. & Kelly, J. W. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc. Natl. Acad. Sci. USA 99(Suppl 4), 16427\u201316432. https:\/\/doi.org\/10.1073\/pnas.202495199 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71446_CR8","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer, M. S. et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379, 1007\u20131016. https:\/\/doi.org\/10.1056\/NEJMoa1805689 (2018).","journal-title":"N. Engl. J. Med."},{"key":"71446_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153 (2018).","journal-title":"N. Engl. J. Med."},{"key":"71446_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams, D. et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: A randomized clinical trial. Amyloid 30, 1\u20139. https:\/\/doi.org\/10.1080\/13506129.2022.2091985 (2023).","journal-title":"Amyloid"},{"key":"71446_CR11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","volume":"3","author":"JM Griffin","year":"2021","unstructured":"Griffin, J. M. et al. ATTR amyloidosis: Current and emerging management strategies: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 3, 488\u2013505. https:\/\/doi.org\/10.1016\/j.jaccao.2021.06.006 (2021).","journal-title":"JACC CardioOncol."},{"key":"71446_CR12","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Castano","year":"2017","unstructured":"Castano, A. et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur. Heart J. 38, 2879\u20132887. https:\/\/doi.org\/10.1093\/eurheartj\/ehx350 (2017).","journal-title":"Eur. Heart J."},{"key":"71446_CR13","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonzalez-Lopez","year":"2015","unstructured":"Gonzalez-Lopez, E. et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur. Heart J. 36, 2585\u20132594. https:\/\/doi.org\/10.1093\/eurheartj\/ehv338 (2015).","journal-title":"Eur. Heart J."},{"key":"71446_CR14","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/ehf2.13110","volume":"8","author":"K Lindmark","year":"2021","unstructured":"Lindmark, K., Pilebro, B., Sundstrom, T. & Lindqvist, P. Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic. ESC Heart Fail. 8, 745\u2013749. https:\/\/doi.org\/10.1002\/ehf2.13110 (2021).","journal-title":"ESC Heart Fail."},{"key":"71446_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ejhf.2776","volume":"25","author":"A Porcari","year":"2023","unstructured":"Porcari, A. et al. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy. Eur. J. Heart Fail. 25, 515\u2013524. https:\/\/doi.org\/10.1002\/ejhf.2776 (2023).","journal-title":"Eur. J. Heart Fail."},{"key":"71446_CR16","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jacc.2022.06.026","volume":"80","author":"O Westin","year":"2022","unstructured":"Westin, O. et al. Screening for cardiac amyloidosis 5 to 15 years after surgery for bilateral carpal tunnel syndrome. J. Am. Coll. Cardiol. 80, 967\u2013977. https:\/\/doi.org\/10.1016\/j.jacc.2022.06.026 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"71446_CR17","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/ejhf.2589","volume":"24","author":"AS Antonopoulos","year":"2022","unstructured":"Antonopoulos, A. S. et al. Prevalence and clinical outcomes of transthyretin amyloidosis: A systematic review and meta-analysis. Eur. J. Heart Fail. 24, 1677\u20131696. https:\/\/doi.org\/10.1002\/ejhf.2589 (2022).","journal-title":"Eur. J. Heart Fail."},{"key":"71446_CR18","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","volume":"87","author":"P Westermark","year":"1990","unstructured":"Westermark, P., Sletten, K., Johansson, B. & Cornwell, G. G. 3rd. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc. Natl. Acad. Sci. USA 87, 2843\u20132845. https:\/\/doi.org\/10.1073\/pnas.87.7.2843 (1990).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71446_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4137\/CMC.S15719","volume":"8","author":"VK Ton","year":"2014","unstructured":"Ton, V. K., Mukherjee, M. & Judge, D. P. Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction. Clin. Med. Insights Cardiol. 8, 39\u201344. https:\/\/doi.org\/10.4137\/CMC.S15719 (2014).","journal-title":"Clin. Med. Insights Cardiol."},{"key":"71446_CR20","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1021\/bi301313b","volume":"52","author":"L Zhao","year":"2013","unstructured":"Zhao, L., Buxbaum, J. N. & Reixach, N. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry 52, 1913\u20131926. https:\/\/doi.org\/10.1021\/bi301313b (2013).","journal-title":"Biochemistry"},{"key":"71446_CR21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2016072118","author":"X Jiang","year":"2021","unstructured":"Jiang, X. et al. A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction. Proc. Natl. Acad. Sci. USA https:\/\/doi.org\/10.1073\/pnas.2016072118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71446_CR22","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/eurheartj\/ehz695","volume":"41","author":"J George","year":"2020","unstructured":"George, J. et al. A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model. Eur. Heart J. 41, 1260\u20131270. https:\/\/doi.org\/10.1093\/eurheartj\/ehz695 (2020).","journal-title":"Eur. Heart J."},{"key":"71446_CR23","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1021\/bi500171j","volume":"53","author":"I Rappley","year":"2014","unstructured":"Rappley, I. et al. Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry 53, 1993\u20132006. https:\/\/doi.org\/10.1021\/bi500171j (2014).","journal-title":"Biochemistry"},{"key":"71446_CR24","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126526","author":"C Monteiro","year":"2019","unstructured":"Monteiro, C. et al. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.126526 (2019).","journal-title":"JCI Insight"},{"key":"71446_CR25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","volume":"133","author":"LH Connors","year":"2016","unstructured":"Connors, L. H. et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: A prospective. Observ. Cohort Stud. Circ. 133, 282\u2013290. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018852 (2016).","journal-title":"Observ. Cohort Stud. Circ."},{"key":"71446_CR26","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/jalm\/jfaa225","volume":"6","author":"T Iino","year":"2021","unstructured":"Iino, T. et al. Quantification of amyloid-beta in plasma by simple and highly sensitive immunoaffinity enrichment and LC-MS\/MS assay. J. Appl. Lab. Med. 6, 834\u2013845. https:\/\/doi.org\/10.1093\/jalm\/jfaa225 (2021).","journal-title":"J. Appl. Lab. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71446-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71446-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71446-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T15:14:54Z","timestamp":1725376494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71446-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["71446"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-71446-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20508"}}